mitomycin has been researched along with pevonedistat in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hagen, T; Tan, CY | 1 |
Bandi, S; Blank, JL; Bouck, DC; Cosmopoulos, K; Garcia, K; Hather, G; Kuranda, M; Lightcap, ES; Liu, R; Liu, XJ; Pickard, MD; Sappal, DS; Smith, PG; Thomas, MP | 1 |
2 other study(ies) available for mitomycin and pevonedistat
Article | Year |
---|---|
Destabilization of CDC6 upon DNA damage is dependent on neddylation but independent of Cullin E3 ligases.
Topics: Cell Cycle Proteins; Cullin Proteins; Cyclopentanes; DNA Damage; DNA Replication; G1 Phase; HCT116 Cells; HEK293 Cells; HeLa Cells; Humans; Mitomycin; NEDD8 Protein; Nuclear Proteins; Pyrimidines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination; Ubiquitins | 2013 |
Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Chromatin; Cyclopentanes; DNA Damage; Drug Synergism; Humans; Mice; Mitomycin; Pyrimidines; Ubiquitin-Activating Enzymes; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2014 |